Antiproliferative and Antiandrogenic Androstanes
1063
Emerg. Drugs, 11, 111-123 (2006).
Cabeza, M., Heuze, I., Bratoeff, E., Murillo, E., Ramirez, E.,
and Lira, A., New progesterone esters as 5α-reductase
thesis of 7-hydroxydehydroepiandrosterone and 7-hydroxy-
dehydroepiandrosterone. Steroids, 70, 970-973 (2005).
Li, X., Chen, C., Singh, S. M., and Labrie, F., The enzyme
inhibitors. Chem. Pharm. Bull., 49, 1081-1084 (2001).
and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase.
Dhingra, N., Synthesis and study of novel steroidal 5
α-
Steroids, 60, 430-441 (1995).
reductase inhibitors, Ph. D. Thesis. Panjab University,
Chandigarh, (2008).
Lowe, F. C., Treatment of lower urinary tract symptoms
suggestive of benign prostatic hyperplasia: sexual function.
BJU Int., 95 Suppl 4, 12-18 (2005).
Mosmann, T., Rapid colorimetric assay for cellular growth
and survival : Application to proliferation and cytotoxicity
assays. J. Immunol. Methods, 65, 55-63 (1983).
Djavan, B., Remzi, M., Erne, B., and Marberger, M., The
pathophysiology of benign prostatic hyperplasia. Drugs
Today, 38, 867-876 (2002).
Garsky, V. M., Lumma, P. K., Feng, D. M., Wai, J., Ramjit,
H. G., Sardana, M. K, Oliff, A., Jones, R. E., DeFeo-Jones,
D., and Freidinger, R. M., The synthesis of a prodrug of
doxorubicin designed to provide reduced systemic toxicity
and greater target efficacy. J. Med. Chem., 44, 4216-4224
(2001).
Gediya, L. K., Chopra, P., Purushottamachar, P., Maheshwari,
N., and Njar, V. C., A new simple and high-yield synthesis
of suberoylanilide hydroxamic acid and its inhibitory
effect alone or in combination with retinoids on prolifer-
ation of human prostate cancer cells. J. Med. Chem., 48,
5047-5051 (2005).
Gomez-Monterrey, I., Campiglia, P., Grieco, P., Diurno, M.
V., Bolognese, A., La Colla, P., and Novellino, E., New
benzo [g] isoquinoline-5,10-diones and dihydrothieno [2,3-
b]naphtho-4,9-dione derivatives: synthesis and biological
evaluation as potential antitumoral agents. Bioorg. Med.
Chem., 11, 3769-3775 (2003).
Occhiato, E. G., Guarna, A., Danza, G., and Serio, M.,
Selective non-steroidal inhibitors of 5α-reductase type 1.
J. Steroid Biochem. Mol. Biol., 88, 1-16 (2004).
Perez-Stable, C., 2-Methoxyestradiol and paclitaxel have
similar effects on the cell cycle and induction of apoptosis
in prostate cancer cells. Cancer Lett., 231, 49-64 (2006).
Rassaie, M. J., Kumari, L. G., Pandey, P. K., Gupta, N.,
Kochupillai, N., and Grover, P. K., A highly specific
heterologous enzyme-linked immunosorbent assay for
measuring testosterone in plasma using antibody-coated
immunoassay plates or polypropylene tubes. Steroids, 57,
288-294 (1992).
Smith, A. B. and Carson, C. C., Finasteride in the treatment
of patients with benign prostatic hyperplasia: a review.
Ther. Clin. Risk Manag., 5, 535-545 (2009).
Sraddha, T. and Kourals, H., Management of benign
prostatic hyperplasia. J. Pharm. Tech., 21, 330-336 (2005).
Stahl, F., Götz, F., and Dörner, G., Plasma testosterone
levels in rats under various conditions. Exp. Clin.
Endocrinol., 84, 277-284 (1984).
Gududuru, V., Hurh, E., Dalton, J. T., and Miller, D. D.,
Discovery of 2-arylthiazolidine-4-carboxylic acid amides
as a new class of cytotoxic agents for prostate cancer. J.
Med. Chem., 48, 2584-2588 (2005).
Tarter, T. H. and Vaughan, E. D. Jr., Inhibitors of 5α-re-
Harris, G. S. and Kozarich, J. W., Steroid 5
α-reductase
ductase in the treatment of benign prostatic hyperplasia.
inhibitors in androgen-dependent disorders. Curr. Opin.
Chem. Biol., 1, 254-259 (1997).
Hartmann, R. W., Hector, M., Haidar, S., Ehmer, P. B., Reichert,
W., and Jose, J., Synthesis and evaluation of novel ster-
Curr. Pharm. Des., 12, 775-783 (2006).
Valasinas, A., Sarkar, A., Reddy, V. K., Marton, L. J., Basu,
H. S., and Frydman, B., Conformationally restricted
analogues of 1N,14N-bisethylhomospermine (BE-4-4-4):
synthesis and growth inhibitory effects on human pro-
state cancer cells. J. Med. Chem., 44, 390-403 (2001).
Velgova, H. and Kohout, L., 6,7-Secoandrostane derivatives.
Collect. Czech. Chem. Commun., 50, 962-972 (1985).
Vogel, H. G., Drug Discovery and Evaluation: Pharmaco-
logical Assays, 2nd ed. Springer-Verlog, Berlin Heidelberg,
p. 1178, (2002).
oidal oxime inhibitors of P450 17 (17α-hydroxylase / C17-
20-lyase) and 5 -reductase types 1 and 2. J. Med. Chem.,
α
43, 4266-4277 (2000).
Jakobsen, C. M., Denmeade, S. R., Isaacs, J. T., Gady, A.,
Olsen, C. E., and Christensen, S. B., Design, synthesis and
pharmacological evaluation of thapsigargin analogues for
targeting apoptosis to prostatic cancer cells. J. Med.
Chem., 44, 4696-4703 (2001).
Weisser, H., Tunn, S., Debus, M., and Krieg, M., 5α-
Kenny, B., Ballard, S., Blagg, J., and Fox, D., Pharmacological
options in the treatment of benign prostatic hyperplasia.
J. Med. Chem., 40, 1293-1315 (1997).
reductase inhibition by finasteride (Proscar) in epithelium
and stroma of human benign prostatic hyperplasia.
Steroids, 59, 616-620 (1994).
Lepor, H., Pathophysiology of benign prostatic hyperplasia:
Weisskopf, M., Schaffner, W., Jundt, G., Sulser, T., Wyler,
S., and Tullberg-Reinert, H., A Vitex agnus-castus extract
inhibits cell growth and induces apoptosis in prostate
epithelial cell lines. Planta Med., 71, 910-916 (2005).
insights from medical therapy for the disease. Rev. Urol.
,
11 Suppl 1, S9-S13 (2009).
Li, H., Liu, H. M., Ge, W., Huang, L., and Shan, L., Syn-